{"id":"W4410958726","doi":"10.1016/j.annonc.2025.04.003","title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"Genentech; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Daiichi-Sankyo; Gilead Sciences; Servier; Pfizer; Yonsei University; Regeneron Pharmaceuticals; Natera; Seagen; Sanofi; Apollomics; International Association for the Study of Lung Cancer; BeiGene; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Samsung; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Yuhan; Amgen; Celgene","keywords":"Osimertinib; Medicine; Epidermal growth factor receptor; Cancer research; Lung cancer; Oncology; Internal medicine; Receptor; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001418722,0.0008654898,0.001516375,0.0003085101,0.0002568663,0.0009436373,0.000446299,0.0006262754,0.00179852],"category_scores_gemma":[0.0006604175,0.0003014099,0.001886538,0.0003380112,0.0005130211,0.0008392132,0.0002403922,0.001721625,0.0004655935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00100509,"about_ca_system_score_gemma":0.001009516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001195164,"about_ca_topic_score_gemma":0.006130737,"domain_scores_codex":[0.9996148,0.0001806871,0.00001650314,0.00005088878,0.00004869968,0.00008840407],"domain_scores_gemma":[0.9996724,0.00007713473,0.00007781024,0.00002768249,0.00002125305,0.0001236994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6563693,0.02203373,0.0340265,0.001632356,0.006915228,0.0004472068,0.0004553798,0.004548189,0.03674038,0.0008161105,0.008878617,0.227137],"study_design_scores_gemma":[0.4387659,0.3989203,0.1308234,0.0002093385,0.004793595,0.001099882,0.0004423271,0.003988419,0.007275586,0.001088809,0.01249015,0.0001022164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946687,0.002618501,0.0001142954,0.0002346524,0.0000908924,0.0001987775,0.000451072,0.00002834583,0.001594747],"genre_scores_gemma":[0.9937997,0.001977029,0.0004070732,0.0003912348,0.0001251949,0.0002017487,0.001439404,0.00001976507,0.00163877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00179852,"threshold_uncertainty_score":0.007503033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04496678258221625,"score_gpt":0.4243055604986285,"score_spread":0.3793387779164122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}